Abstract | PURPOSE: PATIENTS AND METHODS: Overall, 1,638 patients from 12 countries were enrolled onto a large, prospective multicenter project aimed at describing the clinical history of polycythemia vera for the following outcomes: survival, the cumulative rate of cardiovascular death and thrombosis, the cumulative rate of leukemia, myelodysplasia, and myelofibrosis. The mean duration of the disease at entry and the duration of the follow-up were 4.9 and 2.7 years, respectively. RESULTS: The overall mortality rate of 3.7 deaths per 100 persons per year resulted from a moderate risk of cardiovascular death and a high risk of death from noncardiovascular causes (mainly hematologic transformations). Age older than 65 years and a positive history of thrombosis were the most important predictors of cardiovascular events. Antiplatelet therapy, but not cytoreductive treatment, was significantly associated with a lower risk of cardiovascular events. We found a consistent association between age and risk of leukemia, and between duration of the disease with risk of myelofibrosis. CONCLUSION: The European Collaboration on Low-Dose Aspirin in Polycythemia Vera study documents that large international collaborative studies are feasible in this field, in which few epidemiologic data are available. The persistently high mortality rate from hematologic malignancies characterizes the unmet therapeutic need of polycythemic patients and suggests a priority for future studies in this disease.
|
Authors | Roberto Marchioli, Guido Finazzi, Raffaele Landolfi, Jack Kutti, Heinz Gisslinger, Carlo Patrono, Raphael Marilus, Ana Villegas, Gianni Tognoni, Tiziano Barbui |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 23
Issue 10
Pg. 2224-32
(Apr 01 2005)
ISSN: 0732-183X [Print] United States |
PMID | 15710945
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Topics |
- Aged
- Cardiovascular Diseases
(etiology, mortality)
- Cohort Studies
- Female
- Humans
- Leukemia
(etiology, mortality)
- Male
- Middle Aged
- Polycythemia Vera
(complications, therapy)
- Prospective Studies
- Risk Factors
- Survival Analysis
- Thrombosis
(etiology, mortality)
- Time Factors
|